Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.
Uses described in the label
INDICATIONS AND USAGE Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.
Dosage and administration — label text
DOSAGE AND ADMINISTRATION See product labeling for methotrexate sodium and cytarabine. Elliotts B Solution is intended for intrathecal administration only. Elliotts B Solution does not contain antibacterial preservatives and introduction of contaminated solutions into the cerebrospinal fluid may have extremely serious consequences. Therefore, administration of intrathecal solutions should be accomplished as soon as possible after preparation. A sterile filter-needle should be used to withdraw the contents of the ampule. Intrathecal drug products should be inspected visually for particulate matter and discoloration prior to administration. Preparation and Administration Precautions Elliotts B Solution is a diluent for the cytotoxic anticancer agents, methotrexate sodium and cytarabine. Care should be exercised in the handling and preparation of infusion solutions with these products. (See product labeling for methotrexate sodium and cytarabine.)
Contraindications
CONTRAINDICATIONS None known.
Warnings
WARNINGS Intrathecal administration of drugs such as methotrexate sodium and cytarabine should be performed by personnel skilled in the technique of lumbar puncture under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. The labeling for methotrexate sodium and cytarabine should be consulted.
Adverse reactions
ADVERSE REACTIONS Adverse reactions may occur with any given intrathecal injection due to the chemotherapy or the technique of intrathecal administration. (See product labeling for methotrexate sodium and cytarabine.) Preservative-free methotrexate sodium and cytarabine should be used to minimize adverse reactions due to preservatives. If an adverse reaction does occur, discontinue the administration, evaluate the patient, institute appropriate therapeutic countermeasures and, if possible, save the remainder of the unused solution(s) for examination.
Product description
DESCRIPTION Elliotts B ® Solution is a sterile, nonpyrogenic, isotonic solution containing no bacteriostatic preservatives. Elliotts B Solution is a diluent for intrathecal administration of methotrexate sodium and cytarabine. Each 10 mL of Elliotts B Solution contains: Sodium Chloride, USP 73 mg Sodium Bicarbonate, USP 19 mg Dextrose, USP 8 mg Magnesium Sulfate • 7H 2 O, USP 3 mg Potassium Chloride, USP 3 mg Calcium Chloride • 2H 2 O, USP 2 mg Sodium Phosphate, dibasic • 7H 2 O, USP 2 mg Water for Injection, USP qs 10 mL Concentration of Electrolytes: Sodium 149 mEq/liter Bicarbonate 22.6 mEq/liter Potassium 4 mEq/liter Chloride 132 mEq/liter Calcium 2.7 mEq/liter Sulfate 2.4 mEq/liter Magnesium 2.4 mEq/liter Phosphate 1.5 mEq/liter The formulae and molecular weights of the ingredients are: INGREDIENT MOLECULAR FORMULA MOLECULAR WEIGHT Sodium Chloride NaCl 58.44 Sodium Bicarbonate NaHCO 3 84.01 Dextrose C 6 H 12 O 6 180.16 Magnesium Sulfate • 7H 2 O Mg 2 SO 4 • 7H 2 O 246.48 Potassium Chloride KCl 74.55 Calcium Chloride • 2H 2 O CaCl 2 • 2H 2 O 147.01 Sodium Phosphate, dibasic • 7H 2 O Na 2 HPO 4 • 7H 2 O 268.07 The pH of Elliotts B Solution is 6.0-7.5, and the osmolarity is 288 mOsmol per liter (calculated).
Table text from source:
| Sodium Chloride, USP | 73 mg
| Sodium Bicarbonate, USP | 19 mg
| Dextrose, USP | 8 mg
| Magnesium Sulfate • 7H2O, USP | 3 mg
| Potassium Chloride, USP | 3 mg
| Calcium Chloride • 2H2O, USP | 2 mg
| Sodium Phosphate, dibasic • 7H2O, USP | 2 mg
| Water for Injection, USP | qs 10 mL
| Sodium | 149 mEq/liter | Bicarbonate | 22.6 mEq/liter
| Potassium | 4 mEq/liter | Chloride | 132 mEq/liter
| Calcium | 2.7 mEq/liter | Sulfate | 2.4 mEq/liter
| Magnesium | 2.4 mEq/liter | Phosphate | 1.5 mEq/liter
| INGREDIENT | MOLECULAR FORMULA | MOLECULAR WEIGHT
| Sodium Chloride | NaCl | 58.44
| Sodium Bicarbonate | NaHCO3 | 84.01
| Dextrose | C6H12O6 | 180.16
| Magnesium Sulfate • 7H2O | Mg2SO4 • 7H2O | 246.48
| Potassium Chloride | KCl | 74.55
| Calcium Chloride • 2H2O | CaCl2 • 2H2O | 147.01
| Sodium Phosphate, dibasic • 7H2O | Na2HPO4 • 7H2O | 268.07
Clinical pharmacology
CLINICAL PHARMACOLOGY Elliotts B Solution provides a buffered salt solution for use as a diluent for the intrathecal administration of methotrexate sodium and cytarabine. It has been demonstrated that Elliotts B Solution is comparable to cerebrospinal fluid in pH, electrolyte composition, glucose content, and osmolarity: Comparison of Electrolyte Composition, pH and Nonelectrolytic Constituents of Elliotts B Solution and CSF Solution Na + mEq/L K + mEq/L Ca ++ mEq/L Mg ++ mEq/L HCO 3 - mEq/L Cl - mEq/L pH Phosphorus mg/dL Glucose mg/dL Cerebrospinal Fluid 117-137 2.3-4.6 2.2 2.2 22.9 113-127 7.31 1.2-2.1 45-80 Elliotts B Solution 149 4 2.7 2.4 22.6 132 6.0-7.5 2.3 80 The approximate buffer capacity of Elliotts B Solution is 1.1 X 10 -2 equivalents when the challenge solution is 0.01 N HCl and 7.8 X 10 -3 equivalents when the challenge solution is 0.01 N NaOH. 1 Compatibility studies with methotrexate sodium and cytarabine indicate these drugs are physically compatible with Elliotts B Solution.
Table text from source:
| Solution | Na+ mEq/L | K+ mEq/L | Ca++ mEq/L | Mg++ mEq/L | HCO3- mEq/L | Cl- mEq/L | pH | Phosphorus mg/dL | Glucose mg/dL
| Cerebrospinal Fluid | 117-137 | 2.3-4.6 | 2.2 | 2.2 | 22.9 | 113-127 | 7.31 | 1.2-2.1 | 45-80
| Elliotts B Solution | 149 | 4 | 2.7 | 2.4 | 22.6 | 132 | 6.0-7.5 | 2.3 | 80
Precautions
PRECAUTIONS General Particular attention should be taken to assure the maintenance of sterile technique throughout the procedure. (See DOSAGE AND ADMINISTRATION .) Carcinogenesis, Mutagenesis, Impairment of Fertility No standard mutagenicity or carcinogenicity studies have been conducted with Elliotts B Solution. Usage in Pregnancy All components of Elliotts B Solution are normal body constituents. Animal reproduction studies have not been conducted with Elliotts B Solution.
General precautions
General Particular attention should be taken to assure the maintenance of sterile technique throughout the procedure. (See DOSAGE AND ADMINISTRATION .)
Carcinogenesis and mutagenesis and impairment of fertility
Carcinogenesis, Mutagenesis, Impairment of Fertility No standard mutagenicity or carcinogenicity studies have been conducted with Elliotts B Solution.
Pregnancy
Usage in Pregnancy All components of Elliotts B Solution are normal body constituents. Animal reproduction studies have not been conducted with Elliotts B Solution.
Drug abuse and dependence
DRUG ABUSE AND DEPENDENCE There is no potential for drug abuse or drug dependence.
Overdose information
OVERDOSAGE Elliotts B Solution is a diluent. In the event of a drug, fluid or solute overload following administration, evaluate the patient's condition, and institute appropriate corrective treatment. (See product labeling for methotrexate sodium and cytarabine.)
Supply and packaging
HOW SUPPLIED NDC SIZE 55792-007-10 10 mL ampule Elliotts B Solution is available in single-use clear glass ampules, packaged 10 ampules per box. Store at controlled room temperature, 20ºC-25ºC (68ºF-77ºF) [See USP]. Preservative Free. Discard unused portion. Use only if solution is clear and ampule is intact. Distributed by: Lukare Medical, LLC Ponte Vedra Beach, FL 32082 1-855-752-9317 www.elliottsbsolution.com
Table text from source:
| NDC | SIZE
| 55792-007-10 | 10 mL ampule
References
REFERENCES: 1. Cradock JC, et al. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytara‑bine and hydrocortisone sodium succinate. American Journal of Hospital Pharmacy (1978); 35:402. Rev. 05/2024
The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.